DOCUMENT RESOURCES FOR EVERYONE
Documents tagged
Documents Mycobacterium

Mycobacterium Important Human Pathogens Mycobacterium tuberculosis Mycobacterium leprae (uncommon) Mycobacterium avium-intracellulaire Complex (MAC) or (M. avium) Lipid-Rich…

Health & Medicine 3. detection and treatment

1. DETECTION ANDTREATMENT 2. India’s policy on HIV testing Voluntary, Informed, Confidential and Free HIVtesting Mandatory HIV testing of Blood and bloodproducts…

Health & Medicine Impact of Chronic HCV Co-infection on HIV Clinical Outcomes in the District of Columbia

1. Impact of Chronic HCV Co-infectionon HIV Clinical Outcomes in the District of Columbia Sarah Willis, MPH Department of Epidemiology and BiostatisticsSchool of Public Health…

Health & Medicine Evaluating the National HIV/AIDS Strategy with Surveillance Data

1. Evaluating the National HIV/AIDS Strategy with Surveillance DataH. Irene Hall, PhD, FACE Chief, HIV Incidence and Case Surveillance Branch 2011 National HIV Prevention…

Health & Medicine Gw unity feb_09

1. Unity's Response to the HIV Epidemic Andrew Catanzaro, MD Unity Health Care, Inc. 2. Overview Unity Health Care, Inc. History, Mission, Vision Patient demographics…

Documents TB VACCINES: Whats New?? Dr S G KASI Consultant Pediatrician Bengaluru.

Slide 1TB VACCINES: Whats New?? Dr S G KASI Consultant Pediatrician Bengaluru Slide 2 Existing TB Vaccine Ineffective BCG unreliable against pulmonary TB, which accounts…

Documents Workshop 4: Il late-presenter Moderatori: G. Ippolito, M. Moroni Discussant: R. Iardino Limportanza....

Slide 1Workshop 4: Il late-presenter Moderatori: G. Ippolito, M. Moroni Discussant: R. Iardino Limportanza della risposta immunologica S. Rusconi Slide 2 Il late-presenter:…

Documents Workshop 5: Il coinfetto Moderatori: G. Angarano, V. Vullo Discussant: A. Cerioli Quando e come...

Slide 1Workshop 5: Il coinfetto Moderatori: G. Angarano, V. Vullo Discussant: A. Cerioli Quando e come cominciare P. Nasta Slide 2 Guidelines and Clinical Expertise: the…

Documents COMPUTER INTENSIVE AND RE-RANDOMIZATION TESTS IN CLINICAL TRIALS Thomas Hammerstrom, Ph.D. USFDA,...

Slide 1COMPUTER INTENSIVE AND RE-RANDOMIZATION TESTS IN CLINICAL TRIALS Thomas Hammerstrom, Ph.D. USFDA, Division of Biometrics The opinions expressed are those of the author…

Documents Surrogate Endpoints: A Regulatory View Greg Campbell, Ph.D. Director, Division of Biostatistics...

Slide 1Surrogate Endpoints: A Regulatory View Greg Campbell, Ph.D. Director, Division of Biostatistics Center for Devices and Radiological Health Food and Drug Administration…